Leqembi's accelerated approval sees Eisai upholding its part of the bargain, setting a reasonable price and moving fast with confirmatory data.
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Sunlenca gets a US green light at the second time of asking, but combination success will be vital to it fulfilling its promise.
The approval is good for CSL, and better for Uniqure.
EQRX tears up plans to challenge US PD-(L)1 players on price, and switches focus to two non-discounted small molecules.